FLT3 Inhibitors Upregulate CXCR4 and E-selectin Ligands via Erk Suppression in Aml Cells and CXCR4/E-selectin Inhibition Enhances Anti-leukemia Efficacy of FLT3-Targeted Therapy in AML

Authors

Yannan Jia
Weiguo Zhang
Mahesh Basyal
Kyung Hee Chang
Lauren Ostermann
Jared K Burks
Charlie Ly
Hong Mu-Mosley
Qi Zhang
Xin Han
William E Fogler
John L Magnani
Arnaud Lesegretain
Anna A Zal
Tomasz Zal
Michael Andreeff

Language

English

Publication Date

6-1-2023

Journal

Leukemia

DOI

10.1038/s41375-023-01897-x

PMID

37085610

PMCID

PMC10244167

PubMedCentral® Posted Date

4-21-2023

PubMedCentral® Full Text Version

Post-print

Keywords

Humans, E-Selectin, fms-Like Tyrosine Kinase 3, Leukemia, Myeloid, Acute, Ligands, Mutation, Protein Kinase Inhibitors, Receptors, CXCR4, Signal Transduction, MAP Kinase Signaling System

Published Open-Access

yes

Recommended Citation

Jia, Yannan; Zhang, Weiguo; Basyal, Mahesh; et al., "FLT3 Inhibitors Upregulate CXCR4 and E-selectin Ligands via Erk Suppression in Aml Cells and CXCR4/E-selectin Inhibition Enhances Anti-leukemia Efficacy of FLT3-Targeted Therapy in AML" (2023). Faculty, Staff and Student Publications. 5282.
https://digitalcommons.library.tmc.edu/uthgsbs_docs/5282